Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer

Steven H. Lin, Kenneth W. Merrell, Jincheng Shen, Vivek Verma, Arlene M. Correa, Lu Wang, Peter F. Thall, Neha Bhooshan, Sarah E. James, Michael G. Haddock, Mohan Suntharalingam, Minesh P. Mehta, Zhongxing Liao, James D. Cox, Ritsuko Komaki, Reza J. Mehran, Michael D. Chuong, Christopher L. Hallemeier

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Purpose Relative radiation dose exposure to vital organs in the thorax could influence clinical outcomes in esophageal cancer (EC). We assessed whether the type of radiation therapy (RT) modality used was associated with postoperative outcomes after neoadjuvant chemoradiation (nCRT). Patients and methods Contemporary data from 580 EC patients treated with nCRT at 3 academic institutions from 2007 to 2013 were reviewed. 3D conformal RT (3D), intensity modulated RT (IMRT) and proton beam therapy (PBT) were used for 214 (37%), 255 (44%), and 111 (19%) patients, respectively. Postoperative outcomes included pulmonary, GI, cardiac, wound healing complications, length of in-hospital stay (LOS), and 90-day postoperative mortality. Cox model fits, and log-rank tests both with and without Inverse Probability of treatment Weighting (IPW) were used to correct for bias due to non-randomization. Results RT modality was significantly associated with the incidence of pulmonary, cardiac and wound complications, which also bore out on multivariate analysis. Mean LOS was also significantly associated with treatment modality (13.2 days for 3D (95%CI 11.7–14.7), 11.6 days for IMRT (95%CI 10.9–12.7), and 9.3 days for PBT (95%CI 8.2–10.3) (p < 0.0001)). The 90 day postoperative mortality rates were 4.2%, 4.3%, and 0.9%, respectively, for 3D, IMRT and PBT (p = 0.264). Conclusions Advanced RT technologies (IMRT and PBT) were associated with significantly reduced rate of postoperative complications and LOS compared to 3D, with PBT displaying the greatest benefit in a number of clinical endpoints. Ongoing prospective randomized trial will be needed to validate these results.

Original languageEnglish (US)
Pages (from-to)376-381
Number of pages6
JournalRadiotherapy and Oncology
Issue number3
StatePublished - Jun 2017


  • Esophageal carcinoma
  • Intensity modulated radiation therapy
  • Postoperative complications
  • Proton beam therapy
  • Radiation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer'. Together they form a unique fingerprint.

Cite this